Abstract
ObjectivesTo evaluate the effectiveness of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better.MethodsGeneral meta-analysis was performed to produce polled estimates of the effect of mortality, inflammatory factors, and lung function index in COPD patients by the search of PubMed, Web of Science, Embase, and China National Knowledge Infrastructure for eligible studies. A network meta-analysis was performed to synthetically compare the effectiveness of using different statins in COPD patients.ResultsGeneral meta-analysis showed that using statins reduced the risk of all-cause mortality, heart disease-related mortality and COPD acute exacerbation (AECOPD) in COPD patients, the RR (95% CI) were 0.72 (0.63,0.84), 0.72 (0.53,0.98) and 0.84 (0.79,0.89), respectively. And using statins reduced C-reactive protein (CRP) and pulmonary hypertension (PH) in COPD patients, the SMD (95% CI) were − 0.62 (− 0.52,-0.72) and − 0.71 (− 0.85,-0.57), respectively. Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Fluvastatin (76.0%) and Atorvastatin (75.4%) had higher cumulative probability than other satins in reducing PH in COPD patients.ConclusionsUsing statins can reduce the risk of mortality, the level of CRP and PH in COPD patients. In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients.
Highlights
Comorbidities associated with chronic obstructive pulmonary disease (COPD) are important aspect of the disease; in particular, cardiovascular disease (CVD) has been shown to be greater than 2 times more prevalent in COPD patients compared with normal population [3, 4]
Using statins reduced the risk of all-cause mortality and cause-specific mortality Random effect models analyses showed that using statins significantly reduced the risk of all-cause mortality, the relative risk (RR) was 0.72 (0.63, 0.84), with a significant strong heterogeneity (I2 = 86.8%, P < 0.01)
Our study used general meta-analysis to estimate the relative risk of morality in using statins, and used network meta-analysis to estimate standardized mean difference between different statins, and to further determine their effectiveness in COPD in reducing inflammatory factors and increasing lung function index, and the most important is to find which statins have more effective for treating COPD patients
Summary
To evaluate the effectiveness of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
